What Changed
- GE HealthCare reports third quarter 2026 financial results
- The Patient Care Solutions CEO at GE HealthCare (GEHC) receives 1,018 stock units and 2,589 options.
- GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial
Price Move History
- Daily moves over 5%
- 7 252 sessions, November 19, 2025 to November 19, 2026
- Largest daily move
- -13.2% close of April 29, 2026
- 1-year change
- +13.2% closing prices, November 19, 2025 to November 19, 2026
- 1-month change
- +17.4% closing prices, October 19, 2026 to November 19, 2026
Company Description
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider operating in the medical technology and pharmaceutical diagnostics space. According to the company, it focuses on innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. GE HealthCare states that it aims to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier, while simplifying the patient journey across care pathways.
GE HealthCare operates through four primary businesses: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Together, these businesses support patient care from screening and diagnosis to therapy and monitoring, reflecting the company’s focus on the full continuum of care. In industry classifications, GE HealthCare is associated with irradiation apparatus manufacturing within the broader manufacturing sector, which aligns with its activities in diagnostic imaging and related technologies.
The company describes itself as a trusted partner to hospitals and health systems and notes that it has been serving patients and providers for more than 125 years. Over this period, GE HealthCare highlights a heritage at the intersection of medicine and technology, particularly in medical imaging. It emphasizes that its portfolio includes medical technology devices, pharmaceutical diagnostic products, and digital and AI-enabled solutions that support more personalized, connected and compassionate care.
GE HealthCare reports that it is a global healthcare solutions provider, with activities that include collaborations with public and private healthcare systems and academic institutions. For example, the company has announced agreements to supply advanced CT scanners to public hospitals in Indonesia under a national program, and it has described multi-year alliances with healthcare systems such as the University of Rochester Medical Center to support advanced diagnostic imaging, radiopharmaceutical tracer production, and standardized patient monitoring across health systems. These examples illustrate how GE HealthCare positions its technologies within broader healthcare ecosystems.
In addition to imaging hardware and patient monitoring systems, GE HealthCare highlights its work in AI-enabled and cloud-first solutions. The company describes integrating AI, data analytics, and cloud-based platforms into its devices and workflows to support more efficient clinical operations and more precise diagnostic and therapeutic decisions. It has referenced AI-powered tools in areas such as mammography image reconstruction, cardiovascular ultrasound, and radiology workflow software, as well as collaborations that explore automation and autonomous imaging concepts.
GE HealthCare also notes that it develops and supplies pharmaceutical diagnostics, including radiopharmaceutical agents used in imaging. In its public communications, the company links these diagnostics with its imaging systems to support precision medicine approaches, such as molecular imaging and theranostics programs in oncology and cardiology. This combination of devices, diagnostics, and digital tools is presented as central to its approach to advancing precision care.
The company has indicated that it invests substantially in research and development to support new technologies across disease states and care pathways. It has publicly referenced multi-billion-dollar R&D investment over recent years to drive what it calls an innovation renaissance in areas such as CT, MRI, ultrasound, mammography, radiopharmaceuticals, and AI-enabled software. GE HealthCare also points to strategic collaborations with organizations including academic medical centers and technology companies to accelerate development in fields like radiation therapy, oncology, and radiology workflow.
According to its own descriptions, GE HealthCare employs tens of thousands of colleagues worldwide and generates annual revenue in the tens of billions of dollars. The company emphasizes that its workforce and scale are focused on creating what it describes as a world where healthcare has no limits, and it highlights recognition such as being named among Fortune’s World’s Most Admired Companies as an indicator of its standing in the healthcare industry.
From a capital markets perspective, GE HealthCare Technologies Inc. is a Delaware corporation with its common stock listed on Nasdaq under the symbol GEHC. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K. Recent 8-K filings describe, among other matters, the issuance of senior notes and entry into a senior unsecured term loan credit facility, as well as the use of proceeds in connection with an announced acquisition. These filings provide additional detail on the company’s financial obligations and capital structure.
GE HealthCare’s public disclosures also reference its role in supporting health systems in areas such as early diagnosis of non-communicable diseases, expansion of diagnostic access, and development of training and innovation hubs. The company has described initiatives such as regional innovation and training centers and collaborations aimed at capacity building and knowledge transfer, which it associates with strengthening local healthcare ecosystems.
Business Segments and Activities
GE HealthCare identifies four main business areas:
- Imaging – focused on medical imaging technologies used for screening, diagnosis, and guidance across a range of clinical applications.
- Advanced Visualization Solutions – software and related technologies that support image interpretation, workflow, and clinical decision-making.
- Patient Care Solutions – technologies that support patient monitoring and care across various care settings.
- Pharmaceutical Diagnostics – diagnostic agents, including radiopharmaceuticals, used in imaging to support precision diagnosis and treatment planning.
These businesses are described by the company as working together to improve patient care from initial screening and diagnosis through therapy and ongoing monitoring.
Industry and Sector Context
Within industry classifications, GE HealthCare is associated with irradiation apparatus manufacturing, reflecting its involvement in medical imaging and related technologies. More broadly, it operates in the manufacturing sector with a focus on healthcare. The company’s communications emphasize that its technologies and diagnostics are used in hospitals, health systems, and clinical practices worldwide to support radiology, oncology, cardiology, and other clinical disciplines.
Capital Structure and Regulatory Filings
GE HealthCare’s SEC filings indicate that it is an SEC-registered issuer with a Commission File Number of 001-41528 and that it is incorporated in Delaware. In a recent Form 8-K, the company reported entering into a three-year senior unsecured term loan credit facility and issuing senior notes due in 2028 and 2035. The company stated that it intends to use the net proceeds from these financings, together with cash on hand, to pay the purchase price of a previously announced acquisition of Intelerad Medical Systems. Other 8-K filings have reported quarterly financial results and changes in board composition.
Recognition
GE HealthCare has stated that it is proud to be among Fortune’s World’s Most Admired Companies. The company presents this recognition as consistent with its long history in medical technology and its focus on advancing personalized, connected, and compassionate care.
Stock Performance
GE HealthCare Technologies (GEHC) closed at $81.89 on November 19, 2026. Over the past 12 months, the price has gained 13.2%.
GEHC Metrics & Rankings
Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
GE HealthCare Technologies has 10 recent news articles, with the latest published on . Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, AI, earnings. View all GEHC news →
SEC Filings
GE HealthCare Technologies has filed 10 recent SEC filings, including 3 Form 4, 3 Form 8-K, 2 Form 3, 1 Form 144. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GEHC SEC filings →
Financial Highlights
GE HealthCare Technologies generated $20.6B in revenue in FY2025, retaining a 40.0% gross margin, operating income reached $2.8B (13.4% operating margin), and net income was $2.1B, reflecting a 10.1% net profit margin. Diluted earnings per share stood at $4.55. The company generated $2.0B in operating cash flow. The current ratio was 1.37, measuring current assets divided by current liabilities.
Upcoming Events
RSNA 2026 demo
RSNA presentation
SOFIE acquisition close
Board appointment
CT installation completion
GE HealthCare Technologies has 5 upcoming scheduled events. The next event, "RSNA 2026 demo", is scheduled for November 29, 2026 (in 10 days). Investors can track these dates to stay informed about potential catalysts that may affect the GEHC stock price.
Short Interest History
Short interest in GE HealthCare Technologies (GEHC) currently stands at 18.3 million shares, down 5.8% from the previous reporting period, representing 4.1% of the float. Since November 2025, short interest has increased by 63.9%.
Days to Cover History
Days to cover for GE HealthCare Technologies (GEHC) currently stands at 4.9 days, down 5.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 123.4%. Across the settlements charted above, it has ranged from 2.0 to 7.5 days.
GEHC Company Profile & Sector Positioning
GE HealthCare Technologies (GEHC) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ. Among dividend-paying stocks, GEHC ranks #2,013 by dividend yield.
Investors comparing GEHC often look at related companies in the same sector, including DexCom, Inc. (DXCM), Koninklijke Philips N.V. (PHG), Edwards Lifesciences Corp (EW), STERIS plc (STE), and Boston Scientific Corporation (BSX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GEHC's relative position within its industry.